Dr. Yang is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
B3.4609
Houston, TX 77030Phone+1 713-745-2794
Summary
- I am a board certified Pathology with training in molecular pathology from MD Anderson Cancer Center.
Education & Training
- University of Wisconsin Hospitals and ClinicsResidency, Pathology-Anatomic and Clinical, 2014 - 2018
- University of Wisconsin School of Medicine & Public HealthClass of 2014
- University of KansasKS, Microbiology, Summa Cum Laude, 2002 - 2006
- University of KansasMicrobiology, Chemistry, With Highest Distinction, 2002 - 2006
Certifications & Licensure
- TX State Medical License 2020 - 2025
- WI State Medical License 2016 - 2021
- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
- American Board of Pathology Pathology - Molecular Genetic
Awards, Honors, & Recognition
- Excellence in Teaching Award in Molecular Genetic Pathology MD Anderson Cancer Center, 2022, 2024
- Research Award MD Anderson Cancer Center Pathology Department, 2019
- Division of Pathology and Laboratory Medicine Research Award MD Anderson Cancer Center, 2019
- Join now to see all
Publications & Presentations
PubMed
- Routine Clinical Liquid Biopsy Testing for Solid Tumors Delivers the Promise of Minimally Invasive Detection of Genomic Variants With a Faster Turnaround Time.Peng Wang, Richard Kenneth Yang, Fatima Zahra Jelloul, Rajyalakshmi Luthra, Mark J Routbort
JCO Precision Oncology. 2025-03-01 - Melanoma With RNF11::BRAF Fusion: A Novel Fusion Previously Undescribed in Melanoma.Yan Gao, Richard K Yang, Jonathan L Curry, Carlos A Torres-Cabala, Woo Cheal Cho
The American Journal of Dermatopathology. 2025-02-25 - Mitochondrial defects and metabolic vulnerabilities in Lynch syndrome-associated MSH2-deficient endometrial cancer.Mikayla Borthwick Bowen, Brenda Melendez, Qian Zhang, Diana Moreno, Leah Peralta
JCI Insight. 2025-02-18
Journal Articles
- Original Contribution Expression Pattern of Androgen Receptor and AR-V7 in Androgen Deprivation Therapy Naïve Salivary Duct Carcinomas☆Richard K Yang, Rong Hu, ScienceDirect
- Primary myelofibrosis with an unusual MPL mutation: Integrating molecular testing into the diagnosis and prognosis of BCR-ABL1 negative myeloproliferative neoplasmsYang RK, Yang DT, Case of the Quarter- Society for Hematopathology/American Society of Clinical Pathology, 1/1/2015
Abstracts/Posters
- Prognostic value of tumor mutational burden using a 409 gene NGS panel in cancer patients with advanced stage recurrent or treatment refractory disease. Abstract #3245.Yang RK, Wang P, Jelloul F, Routbort M, Kopetz S, Shaw K, Lee J, Zhang J, Chen H, Patel KP, Luthra R, Broaddus RR, AACR 2019 Annual Meeting, Atlanta, GA, 1/29/2019
- Context-Dependent Impact of Tumor Mutation Burden (TMB) on Overall Survival in Patients with Advanced Cancers Resistant to Front-Line Therapy.Yang RK, Routbort M, Wang P, Jelloul FZ, Patel KP, Luthra R, Broaddus RR, Representing MD Anderson Cancer Center. Houston Society of Clinical Pathologists (HSCP) Annual Meeting, H. Stephen Gallager Residents and Fellows Seminar, 1/27/2019
- Utilization of a 409 Gene NGS Panel for Prognostic and Predictive Biomarkers in Immune Checkpoint Blockade Treatment of Advanced Stage Recurrent or Treatment Refractor...Yang RK, Wang P, Jelloul R, Routbort M, Kopetz S, Shaw K, Lee J, Zhang J, Chen H, Roy-Chowdhuri S, Patel KP, Luthra R, Broaddus RR, 5th annual Immuno-Oncology Young Investigators� Forum, Houston, TX, 1/25/2019
- Join now to see all
Press Mentions
- Biolinq Names Diabetes Industry Expert Richard Yang Chief Executive OfficerNovember 12th, 2020
- Society of Hematopathology Quarterly Case Winter 2016: Primary Myelofibrosis with an Unusual MPL Mutation: Integrating Molecular Testing into the Diagnosis and Prognosis of BCR-ABL1 Negative Myeloproliferative Neoplasms. WMSH1601March 3rd, 2016
Professional Memberships
- Fellow
Other Languages
- Chinese (Mandarin), Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: